The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Liraglutide and Renal Outcomes in Type 2 Diabetes
Open accessAbstract
BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown. METHODS: We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo. The secondary renal outcome was a composite of new-onset persistent macroalbuminuria, persistent doubling of the serum creatinine level, end-stage renal disease, or death due to renal disease. The risk of renal outcomes was determined with the use of time-to-event analyses with an intention-to-treat approach. Changes in the estimated glomerular filtration rate and albuminuria were also analyzed. RESULTS: A total of 9340 patients underwent randomization, and the median follow-up of the patients was 3.84 years. The renal outcome occurred in fewer participants in the liraglutide group than in the placebo group (268 of 4668 patients vs. 337 of 4672; hazard ratio, 0.78; 95% confidence interval [CI], 0.67 to 0.92; P=0.003). This result was driven primarily by the new onset of persistent macroalbuminuria, which occurred in fewer participants in the liraglutide group than in the placebo group (161 vs. 215 patients; hazard ratio, 0.74; 95% CI, 0.60 to 0.91; P=0.004). The rates of renal adverse events were similar in the liraglutide group and the placebo group (15.1 events and 16.5 events per 1000 patient-years), including the rate of acute kidney injury (7.1 and 6.2 events per 1000 patient-years, respectively). CONCLUSIONS: This prespecified secondary analysis shows that, when added to usual care, liraglutide resulted in lower rates of the development and progression of diabetic kidney disease than placebo. (Funded by Novo Nordisk and the National Institutes of Health; LEADER ClinicalTrials.gov number, NCT01179048 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The LEADER and REWIND trials also report a greater than 20% reduction in the risk of developing new macroalbuminuria, along with favourable trends in other clinically relevant adverse renal outcomes. 26,27”
The cited source says what the claim attributes to it.
In the citing paper
“Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) have also been shown to improve kidney outcomes (95-100).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [97]
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1 RAs have also been shown to improve kidney outcomes (104-109).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [106]
In the citing paper
“However, the composite kidney outcomes in these trials were evaluated as secondary outcomes, and the reported effects were largely driven by a lower risk of new-onset macroalbuminuria. 23-25”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [24]
In the citing paper
“Treatment with these drugs is in fact associated with a reduced decline in the estimated glomerular filtration rate (eGFR), as well as with a reduction in urinary albumin excretion and in the incidence rate of de novo albuminuria [28,29].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [28]
In the citing paper
“However, these benefits were driven by a lower risk of persistent macroalbuminuria [6,10,13].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationEffects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationStevens, P. E., Levin, A., & for the Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members* (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-11-201306040-00007 · Cited by 3,607
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate
Stevens, L. A., Coresh, J., Greene, T., & Levey, A. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra054415 · Cited by 2,952
Flagged first, then by citations
1 of the 32 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 601–700 of 1,000
Emerging Preventive Strategies in Chronic Kidney Disease: Recent Evidence and Gaps in Knowledge
Pradhan, N., & Dobre, M. A. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01172-5 · Cited by 14
Exploring Liraglutide’s mechanism in reducing renal fibrosis: the Fsp1-CoQ10-NAD(P)H pathway
Chen, Q., Song, J., Zhang, Z., An, J., Gou, Y., Tan, M., & Zhao, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-85658-z · Cited by 14
Krishnan, A., Schneider, C. V., Mukherjee, D., Woreta, T. A., & Alqahtani, S. A. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70069 · Cited by 14
Nair, M., Martin, W. P., Zhernovkov, V., Elliott, J. A., Fearon, N. M., Eckhardt, H., McCormack, J., Godson, C., Brennan, E. P., Marai, M., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001113 · Cited by 14
Liraglutide protects against high-fat diet-induced kidney injury by ameliorating apoptosis
LIANG, R., Wang, M., Fu, C. L., Liang, H., Deng, H., Tan, Y. C. R. S., Xu, F. L., & Cai, M. (2020) · Endocrine Connections · doi:10.1530/ec-20-0294 · Cited by 14
Patel, D. K. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13224 · Cited by 14
Glucagon-Like Peptide-1 Receptor Agonists—Use in Clinical Practice
Tricò, D., & Solini, A. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.04.002 · Cited by 14
Lee, J., Kim, H., Song, K., Yoo, S. J., Han, K., & Lee, S. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2023.1765 · Cited by 14
Wang, M., Cai, X., LIANG, R., Zhang, E.-M., Liang, X.-Q., Liang, H., Fu, C. L., Zhou, A.-D., Shi, Y. Y., Xu, F. L., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115515 · Cited by 14
Incretin Therapies for Patients with Type 2 Diabetes and Chronic Kidney Disease
Alicic, R. Z., & Neumiller, J. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010201 · Cited by 14
Haneda, M., Kadowaki, T., Ito, H., Sasaki, K., Hiraide, S., Ishii, M., Matsukawa, M., & Ueno, M. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0416-2 · Cited by 14
Vaduganathan, M., White, W. B., Charytan, D. M., Morrow, D. A., Liu, Y., Zannad, F. M., Cannon, C. P., & Bakris, G. L. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.10.035 · Cited by 14
Rodríguez, R., Escobedo, B., Lee, A. Y., Thorwald, M. A., Godoy-Lugo, J. A., Nakano, D., Nishiyama, A., Parkes, D. G., & Ortiz, R. M. (2019) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13206 · Cited by 14
The landscape of diabetic kidney disease transformed
Tuttle, K. R. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0240-6 · Cited by 14
Sacre, J. W., Magliano, D. J., & Shaw, J. E. (2020) · Diabetes Care · doi:10.2337/dc20-0654 · Cited by 14
SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes
Jensen, S. K., Heide‐Jørgensen, U., Andersen, I. T., Bonnesen, K., Fu, E. L., Thomsen, R. W., & Christiansen, C. F. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.7409 · Cited by 13
Podder, D., Stala, O., Miah, A., Agyapong, A., Moore, M. E., Hirani, R., Diegisser, D., Garcia, V. G., & Etienne, M. (2026) · Diabetology · doi:10.3390/diabetology7030046 · Cited by 13
Treatment options for managing obesity in chronic kidney disease
Parvathareddy, V. P., Ella, K. M., Shah, M., & Navaneethan, S. D. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000727 · Cited by 13
Risk of developing chronic kidney disease in young-onset Type 2 diabetes in Korea
Lee, J., Lee, S., Yoon, K., Cho, J., Han, K., & Yang, Y. (2023) · Scientific Reports · doi:10.1038/s41598-023-36711-2 · Cited by 13
Grygiel‐Górniak, B., & Skoczek, W. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185814 · Cited by 13
Martos, N., Vergara, A., Llorens-Cebrià, C., Motto, A. E., Martínez-Díaz, I., Gonçalves, F., Garcias-Ramis, M. M., Allo-Urzainqui, E., Narváez, A., Bermejo, S., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1415879 · Cited by 13
Teng, Y., Fan, X., Yu, R., & Yang, X. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01805-z · Cited by 13
Diker‐Cohen, T., Rudman, Y., Turjeman, ., Akirov, A., Steinmetz, T., Calvarysky, B., & Dotan, I. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101624 · Cited by 13
Podocyturia an emerging biomarker for kidney injury
Hanna, C., Etry, H. E., Ibrahim, M., Khalife, L., Bahous, S. A., & Faour, W. H. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04039-w · Cited by 13
Novel Antidiabetic Drugs and Risk of Venous Thromboembolism: A Literature Review
Chen, Q., Anijs, R. J. S., Verlaan, J. P. L., Scheres, L. J. J., Klok, F. A., & Cannegieter, S. C. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2546-0353 · Cited by 13
Wen, S., Yuan, Y., Li, Y., Xu, C., Chen, L., Ren, Y., Wang, C., He, Y., Li, X., Gong, M., et al. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01985-2 · Cited by 13
Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 Diabetes
Derington, C. G., Sarwal, A., Wei, G., Hartsell, S. E., Throolin, M. J., Singh, R., Nevers, M. R., Zhang, C., Katkam, N., Takyi, A., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.37297 · Cited by 13
Martin, W. P., Tuohy, C., Doody, A., Jackson, S., Canavan, R. J., Slattery, D., Twomey, P. J., McKenna, M. J., le Roux, C. W., & Docherty, N. G. (2020) · Scientific Reports · doi:10.1038/s41598-020-71684-6 · Cited by 13
Hirose, N., Tsujimoto, N., Katayose, T., & Chin, R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14600 · Cited by 13
Hypertension mediated kidney and cardiovascular damage and risk stratification: Redefining concepts
Márquez, D. F., Rodríguez‐Sánchez, E., Segura, J., Ruilope, L. M., & Ruiz‐Hurtado, G. (2021) · Nefrología · doi:10.1016/j.nefro.2021.10.003 · Cited by 13
Can Newer Anti-Diabetic Therapies Delay the Development of Diabetic Nephropathy?
Aziz, S., Ghadzi, S. M. S., Sulaiman, S. A. S., Hanafiah, N. H. M., & Harun, S. N. (2021) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/jpbs.jpbs_497_21 · Cited by 13
Wu, H., Lu, Z., Chen, R., Cai, Q., Wang, M., Zhang, L., & Zhu, Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1098032 · Cited by 13
Sagris, D., Ntaios, G., & Milionis, H. J. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-329149 · Cited by 13
Incretins: B eyond type 2 diabetes
Dandona, P., Ghanim, H., & Chaudhuri, A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13153 · Cited by 13
Implementing personalized medicine in diabetic kidney disease: Stakeholders' perspectives
de Vries, J. K., Levin, A., Loud, F. C., Adler, A., Mayer, G. J., & Pena, M. J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13412 · Cited by 13
Baretić, M., Kuŝec, V., & Pavlić-Renar, I. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0517-y · Cited by 13
Ruilope, L. M., Ruiz‐Hurtado, G., Barderas, M. G., de la Cruz, J. J., Lucía, A., de la Sierra, A., Gorostidi, M., Vinyoles, E., Segura, J., Solís, J., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.12921 · Cited by 13
CHILTON, R. J., Dungan, K. M., Shubrook, J. H., & Umpierrez, G. E. (2019) · Primary care diabetes · doi:10.1016/j.pcd.2019.09.008 · Cited by 13
Georgianos, P. I., Vaios, V., Roumeliotis, S. K., Leivaditis, K., Eleftheriadis, T., & Liakopoulos, V. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020223 · Cited by 13
Hsu, W.-C., Lin, C., Chen, J., & Chang, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092653 · Cited by 13
Rheinberger, M., Jung, B., Segiet, T., Nusser, J., Kreisel, G., Andreae, A., Manz, J., Haas, G., Banas, B., Stark, K. J., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213157 · Cited by 13
Tubuloglomerular Feedback in Renal Glucosuria: Mimicking Long-term SGLT-2 Inhibitor Therapy
Neuwirt, H., Burtscher, A., Cherney, D. Z. I., Mayer, G. J., & Ebenbichler, C. F. (2019) · Kidney Medicine · doi:10.1016/j.xkme.2019.09.006 · Cited by 13
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3449 · Cited by 12
Meta-analysis of the association between new hypoglycemic agents and digestive diseases
Wang, Y., Lin, J.-H., & Yang, C.-S. (2022) · Medicine · doi:10.1097/md.0000000000030072 · Cited by 12
Framework of Guidelines for Management of CKD in Asia
Pollock, C. A., Moon, J., Ha, L. P. N., Gojaseni, P., Ching, C. H., Gomez, L., Chan, T. M., Wu, M., Yeo, S. C., Nugroho, P., et al. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.12.010 · Cited by 12
Mahapatro, A., Bozorgi, A., Obulareddy, S. U. J., Jain, S. M., Korsapati, R. R., Kumar, A., Patel, K., Moghadam, S. S., Arya, A., Alotaibi, A. J., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002592 · Cited by 12
Brock, C., Andersen, H., Alibegovic, A. C., Andersen, S. R. D., Andreasen, L., Charles, M., Christensen, D. H., Drewes, A. M., Gall, M.-A., Gylfadottir, S. S., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112010 · Cited by 12
Alammari, N. A., ALSHEHRI, A. S., Khalaf, A. A., Alamri, R., Alhalal, N., Sultan, M. A. A., Ogran, N., Aljohani, R., Alasmari, S. M. S., Alsharif, S. B., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16476 · Cited by 12
Fishkin, A., Rozenberg, A., Schechter, M., Sehtman-Shachar, D. R., Aharon‐Hananel, G., Leibowitz, G., Yanuv, I., & Mosenzon, O. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70066 · Cited by 12
Pharmacotherapy for Obesity: Recent Updates
Fredrick, T. W., Camilleri, M., & Acosta, A. J. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s497904 · Cited by 12
McHugh, K. R., DeVore, A. D., Mentz, R. J., Edmonston, D. L., Green, J. B., & Hernandez, A. F. (2018) · Clinical Cardiology · doi:10.1002/clc.23054 · Cited by 12
Zelniker, T. A., Morrow, D. A., Mosenzon, O., Gurmu, Y., Im, K., Cahn, A., Raz, I., Steg, P. G., Leiter, L. A., Braunwald, E., et al. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2018.298489 · Cited by 12
the ABLE-MET Investigators, Ono, K., Wada, H., Satoh‐Asahara, N., Inoue, H., Uehara, K., Funada, J., Ogo, A., Horie, T., Fujita, M., et al. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00381-1 · Cited by 12
Camacho, R. C., You, S.-H., D’Aquino, K. E., Li, W., Wang, Y., Gunnet, J. W., Littrell, J. B., Qi, J. S., Kang, L., Jian, W., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1794687 · Cited by 12
Intensive management of obesity in people with severe chronic kidney disease: A review
Song, R., Nolan, B. J., Harb, H., & Sumithran, P. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14409 · Cited by 12
González‐Pérez, A., Vizcaya, D., Sáez, M. E., Lind, M., & Rodríguez, L. A. G. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003072 · Cited by 12
Liu, G., Zhong, X., Zheng, J., Zhang, J., Kong, W., Hu, X. F., Min, J., Xia, W., Zeng, T., & Chen, L. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01391-8 · Cited by 12
Singh, P. K., Goyal, L., Mallick, D. C., Surani, S., & Yashi, K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196202 · Cited by 12
Thomson, S. C., & Vallon, V. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-0991-7 · Cited by 12
Liu, W., Yu, J., Tian, T., Miao, J., & Shang, W. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7577 · Cited by 12
GLP-1 Relaxes Rat Coronary Arteries by Enhancing ATP-Sensitive Potassium Channel Currents
Xiong, Q., Fan, S.-H., Li, X., Niu, Y., Wang, J., Zhang, X., Chen, Y.-F., Shi, Y., & Zhang, L.-H. (2019) · Cardiology Research and Practice · doi:10.1155/2019/1968785 · Cited by 12
Sodium‐glucose co‐transporters and diabetic nephropathy: Is there a link with toll‐like receptors?
Jigheh, Z. A., Haghjo, A. G., Argani, H., & Sanajou, D. (2020) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13261 · Cited by 12
Yandrapalli, S., Jolly, G. P., Horblitt, A. M., Pemmasani, G., Sanaani, A., Aronow, W. S., & Frishman, W. H. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000308 · Cited by 12
Osonoi, T., Saito, M., Osonoi, Y., Douguchi, S., Ofuchi, K., & Katoh, M. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0070 · Cited by 12
Kim, Y. A., Lee, Y., & Seo, J. H. (2020) · Journal of Diabetes Research · doi:10.1155/2020/9806790 · Cited by 12
Komorita, Y., Ohkuma, T., Iwase, M., Fujii, H., Ide, H., Oku, Y., Higashi, T., Oshiro, A., Sakamoto, W., Yoshinari, M., et al. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13769 · Cited by 12
Pharmacological Management of Diabetic Nephropathy
Papademetriou, V., Alataki, S., Stavropoulos, K., Papadopoulos, C. E., Bakogiannis, K., & Tsioufis, K. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190405164749 · Cited by 12
Cha-Silva, A. S., Chen, Y., Fazioli, K., Rivara, M. B., & Devine, E. B. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa894 · Cited by 12
GLP-1 receptor agonists, CKD, and eGFR trajectory
van Baar, M. J. B., van Raalte, D. H., & Muskiet, M. H. A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30241-9 · Cited by 12
GLP1R Gene Expression and Kidney Disease Progression
Triozzi, J. L., Yu, Z., Giri, A., Chen, H., Wilson, O. D., Ferolito, B. R., Ikizler, T. A., Akwo, E. A., Robinson‐Cohen, C., Gaziano, J. M., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.40286 · Cited by 11
Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction
Lassen, M. C. H., Ostrominski, J. W., Claggett, B. L., Neuen, B. L., Beldhuis, I. E., Butt, J. H., Biering‐Sørensen, T., Desai, A. S., Lewis, E. F., Jhund, P. S., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.03.042 · Cited by 11
Cardiovascular outcome trials of diabetes drugs: lessons learned
Taylor, S. I., & Leslie, B. R. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99820 · Cited by 11
Persson, F., Charles, M., Povlsen, J. V., & Knudsen, S. T. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.07.003 · Cited by 11
Cases, A. (2023) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2023.09.003 · Cited by 11
Gu, X., Jiang, S., Yang, Y., & Li, W. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01251-2 · Cited by 11
Zhao, X., Liu, Y., Wang, D., Li, T., Xu, Z., Li, Z., Bai, X., & Wang, Y.-C. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5515 · Cited by 11
Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
Packer, M. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.11.052 · Cited by 11
Incretins today: multiple effects and therapeutic potential
Васильевна, Ц. О., Васильевна, В. В., & As, A. (2019) · Diabetes Mellitus · doi:10.14341/dm9841 · Cited by 11
A comprehensive approach to type 2 diabetes mellitus – A recommendation document
Reyes‐García, R., Moreno-Pérez, Ó., Pérez, C. T., Fernández‐García, D., Bellido, V., Casares, M. L. D. L. T., Rozas-Moreno, P., Fernández‐García, J. C., Martínez, A. M., Martín, J. E.-S., et al. (2019) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2018.10.013 · Cited by 11
Nonomura, K., Iizuka, K., Kuwabara-Ohmura, Y., & Yabe, D. (2020) · Internal Medicine · doi:10.2169/internalmedicine.4323-19 · Cited by 11
Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver
Leiva, E. G., & Bril, F. (2020) · Current Hypertension Reviews · doi:10.2174/1573402116999201209203534 · Cited by 11
Advances in clinical research in chronic kidney disease
Zou, Y., Liu, F., Cooper, M. E., & Chai, Z. (2021) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2021-0041 · Cited by 11
Alicic, R. Z., Johnson, E. J., & Tuttle, K. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52978-5.00003-3 · Cited by 11
Epigenetic Contribution to the Development and Progression of Vascular Diabetic Complications
Rodriguez, H., & El‐Osta, A. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7347 · Cited by 11
Effects of sarpogrelate on microvascular complications with type 2 diabetes
Yoo, H., Park, I., Kim, D. J., & Lee, S. (2019) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-019-00794-7 · Cited by 11
Dulaglutide and Insulin: How Can the AWARD Studies Help Guide Clinical Practice?
MacIsaac, R. J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00863-5 · Cited by 11
Chan, A. T. P., & Tang, S. C. W. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.21.285 · Cited by 11
Diagnosis 101: diabetic kidney disease
Lerma, E. V. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac163 · Cited by 11
Decreased expression of the GLP-1 receptor after segmental artery injury in mice
Bjørnholm, K. D., Povlsen, G. K., Ougaard, M. E., Pyke, C., Rakipovski, G., Tveden-Nyborg, P., Lykkesfeldt, J., & Skovsted, G. F. (2021) · Journal of Endocrinology · doi:10.1530/joe-20-0608 · Cited by 10
Jacobs, J. A., Zheutlin, A. R., Derington, C. G., King, J. B., Pandey, A., & Bress, A. P. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100624 · Cited by 10
Practical Approaches to the Management of Cardiorenal Disease Beyond Congestion
Blázquez‐Bermejo, Z., Quiroga, B., Casado, J., de la Espriella, R., Trullàs, J. C., Romero-González, G. A., Rubio‐Gracia, J., Díez, J., Núñez, J. E., de Sequera, P., et al. (2024) · Cardiorenal Medicine · doi:10.1159/000538125 · Cited by 10
Liraglutide ameliorates diabetic kidney disease by modulating gut microbiota and L-5-Oxoproline
Yi, B., Su, K., Cai, Y., Chen, X., Bao, Y., & Wen, Z. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176905 · Cited by 10
Microalbuminuria as a Prognostic Marker in Essential Hypertension
Dimitriadis, K. S., Pyrpyris, N., Vakka, A., Iliakis, P., Theofilis, P., Tatakis, F., Beneki, E., Pitsiori, D., Tsioufis, P., Aznaouridis, K. A., et al. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673348953250310044927 · Cited by 10
Miramontes‐González, J. P., Rodrigo-Alaíz, Á., Gabella-Martín, M., Calle, D. G., Carretero-Gómez, J., & Corral-Gudino, L. (2026) · Diabetes Therapy · doi:10.1007/s13300-025-01829-1 · Cited by 10
Li, T., Chen, K., Sun, Y., & Zhang, L. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1760654 · Cited by 10
Veneti, S., & Τζιόμαλος, Κ. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i9.370 · Cited by 10
The 100 top-cited articles in diabetic kidney disease: a bibliometric analysis
Huang, Z., Zhang, H., Luo, Y., Wei, C., Zhao, Y., Huang, Y., Zhang, L., Chen, W., He, L., Liu, H., et al. (2021) · Renal Failure · doi:10.1080/0886022x.2021.1919528 · Cited by 10
Sabouret, P. F., Angoulvant, D., Pathak, A., Fysekidis, M., Laterra, G., Costa, F., Angelini, F., Bocchino, P. P., Montalescot, G., & Biondi‐Zoccai, G. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.21.04284-1 · Cited by 10
Tsuchida, K., Taneda, S., Yokota, I., Okada, K., Kurihara, Y., Yokoyama, H., Iwamoto, M., Yamazaki, K., Ishigaki, Y., Manda, N., et al. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13877 · Cited by 10
Metadata
- Authors
- Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B.
- Affiliations
- Mount Sinai Hospital (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-08-31
- Volume
- 377
- Issue
- 9
- Pages
- 839-848
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2752707491
- Semantic Scholar
- e3932087f500b455476965939bdced15360eb028
- Cited by
- 1,253
- References
- 32
- Citations by year
- 2026: 99 · 2025: 116 · 2024: 121 · 2023: 131 · 2022: 134 · 2021: 161 · 2020: 180 · 2019: 139 · 2018: 152 · 2017: 20
- FWCI
- 106.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Americanae (AECID Library) (publishedVersion, other-oa)
- ResearchOnline - JCU (James Cook University) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
- Funders
- Novo Nordisk
- National Institutes of Health (UL1TR001111)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- liraglutide, type 2 diabetes, renal outcomes, diabetic nephropathy, macroalbuminuria, end-stage renal disease, acute kidney injury, glucagon-like peptide-1 analogues, albuminuria, estimated glomerular filtration rate, cardiovascular risk, renal adverse effects, LEADER trial, cardiovascular outcomes, serum creatinine doubling, usual care
- MeSH terms
- Liraglutide, Aged, Albuminuria, Creatinine, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Follow-Up Studies, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Kidney Failure, Chronic, Male, Middle Aged, Glucagon-Like Peptide 1, Intention to Treat Analysis, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
